CTXR has momentum on its side & could soon test 12-month highs representing over 100% in gains.
There’s not much time left. Are you ready for today’s alert?
I theorize that among the top 3 reasons most traders miss out on the big gains is the simple act of not taking action at the right time.
But I can’t find the time to prove my theory so you’ll just have to consider it and use it as a basis for taking action.
The type and force of action needed for my newest alert is immediate. The stock has seen an eruption of daily volatility over the last few sessions – the last session saw a volume breakout north of 550%.
So what’s this trade opportunity all about? Hemorrhoids! Don’t laugh because this problem isn’t funny and the profits you could make are very serious.
Citius Pharmaceuticals Inc. (OTCQB: CTXR)
A Hemorrhoid isn’t the sort of thing for which you postpone treatment. Most sufferers would pay a king’s ransom to make them go away so as a business model, my newest trade idea couldn’t have picked a better target market.
You won’t find a better pick either – at least not in the pain space.
CTXR is developing a Hydro-Lido cream to treat hemorrhoids and has reported positive results in a Phase 2a trial. Success at the next level of testing could bring CTXR closer to a market worth north of $1.2B in the US. And since there are millions more people outside of the US with painful bottoms, I suspect CTXR could be in line for a windfall.
At any rate, CTXR is poised and the fact that the company is also trialling treatment for catheter-related bloodstream infections means investors are looking at not one, but two major potential cash cows.
As a near-term trade opportunity CTXR offers both upside and liquidity. The play is trading below its 12-month high of 2.50. RSI, which at the time of writing sits at 54, shows established momentum as well as a window for even greater upward movement.
And how much upside are you looking at relative to a higher bounce up the RSI ladder? At 70 RSI CTXR is trading above 1.36; so from current valuation there is at least 30% upside opportunity available. Not bad by any measure.
Liquidity also makes CTXR very handsome too. A recent 552% volume breakout suggests that investor attention is heating up. This makes it very accessible to those traders who like to go for seconds.
Whether you go for a one-off play or multiple, it doesn’t matter. CTXR is poised to deliver so check it out ASAP.
Check out the chart…
Here’s a link to the chart: http://www.barchart.com/interactive_charts/stocks/CTXR
CTXR (Citius Pharmaceuticals Inc.) is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients.
CTXR was founded in 2007 and is based in Maynard, Massachusetts.
Hemorrhoids Affect 25M People In The Developed World
An estimated 25 million people in the developed world suffer from hemorrhoids, with 10 million in the U.S. alone. Not only that, but issues from this painful problem can lead to more serious health issues. Feel free to Google them. They’re pretty graphic.
Although less common than hemorrhoids, fissures are serious and extremely painful, with approximately 40 percent of cases being chronic and usually requiring surgery. These figures may underestimate the magnitude of the problems, as they are based upon reported contacts between physicians and patients diagnosed with the conditions. Some patients are misdiagnosed or have not sought the advice of a physician due to embarrassment or a feeling that their pain is untreatable or unavoidable.
Citius Pharmaceuticals Addresses Problem That Affects 10 Million People in the U.S.: Hemorrhoids
CTXR recently announced significant progress in its development efforts of its Hydro-Lido cream to treat hemorrhoids. In February, the Company reported results from the Phase 2a trial of its Hydrocortisone and Lidocaine Combination Cream in patients with Grade I and II hemorrhoids, and the data suggest that the Hydro-Lido combination may show faster onset of relief of symptoms and reduction in disease severity as compared to its active components or the cream vehicle.
Citius’ topical Hydro-Lido product is developed to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Hemorrhoids are a common gastrointestinal disorder characterized by pain, swelling, itching, tenderness, and bleeding. Hemorrhoids affect nearly 5% of the U.S. population, with 10 million patients reporting symptoms and a third seeking treatment from doctors. Between 50% and 90% of the population will experience hemorrhoidal disease in their lifetime. The estimated market in the U.S. is over $1.2 billion, and over 25 million units of topical products for hemorrhoids are sold annually in the U.S.
Myron Holubiak, CEO of Citius, said, “As expected, our Phase 2a trial provided insights into optimizing the formulation for our Hydro-Lido hemorrhoid cream. The trial also helped us identify how and when these therapies help patients. Additionally, our recently conducted market research has informed us as to the symptoms that matter most to patients. This data is helping us generate study endpoints that should be both meaningful to the patients and provide a basis for approval by the FDA. This is a large market opportunity; Hydro-Lido would be the first FDA-approved prescription product to treat hemorrhoids in the U.S. We are extremely pleased with our progress.”
To learn more about CTXR please visit their website: http://www.citiuspharma.com/
We have been compensated $32k cash via bank wire by a third party, Microcap Innovations, LLC, to conduct investor relations advertising and marketing for CTXR Stellar Media’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding . Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.